BACKGROUND: The repertoire of serologic tests for identifying a monoclonal gammopathy includes serum and urine protein electrophoresis (PEL), serum and urine immunofixation electrophoresis (IFE), and quantitative serum free light chain (FLC). Although there are several reports on the relative diagnostic contribution of these assays, none has looked at the tests singly and in combination for the various plasma cell proliferative disorders (PCPDs). METHODS: Patients with a PCPD and all 5 assays performed within 30 days of diagnosis were included (n = 1877). The diagnoses were multiple myeloma (MM) (n = 467), smoldering multiple myeloma (SMM) (n = 191), monoclonal gammopathy of undetermined significance (MGUS) (n = 524), plasmacytoma (n = 29), extramedullary plasmacytoma (n = 10), Waldenström macroglobulinemia (WM) (n = 26), primary amyloidosis (AL) (n = 581), light chain deposition disease (LCDD) (n = 18), and POEMS syndrome (n = 31). RESULTS: Of the 1877 patients, 26 were negative in all assays. Omitting urine from the panel lost an additional 23 patients (15 MGUS, 6 AL, 1 plasmacytoma, 1 LCDD), whereas the omission of FLC lost 30 patients (6 MM, 23 AL, and 1 LCDD). The omission of serum IFE as well as urine lost an additional 58 patients (44 MGUS, 7 POEMS, 5 AL, 1 SMM, and 1 plasmacytoma). CONCLUSIONS: The major impact of using a simplified screening panel of serum PEL plus FLC rather than PEL, IFE, and FLC is an 8% reduction in sensitivity for MGUS, 23% for POEMS (7 patients), 4% for plasmacytoma (1 patient), 1% for AL, and 0.5% for SMM. There is no diminution in sensitivity for detecting MM, macroglobulinemia, and LCDD.
BACKGROUND: The repertoire of serologic tests for identifying a monoclonal gammopathy includes serum and urine protein electrophoresis (PEL), serum and urine immunofixation electrophoresis (IFE), and quantitative serum free light chain (FLC). Although there are several reports on the relative diagnostic contribution of these assays, none has looked at the tests singly and in combination for the various plasma cell proliferative disorders (PCPDs). METHODS:Patients with a PCPD and all 5 assays performed within 30 days of diagnosis were included (n = 1877). The diagnoses were multiple myeloma (MM) (n = 467), smoldering multiple myeloma (SMM) (n = 191), monoclonal gammopathy of undetermined significance (MGUS) (n = 524), plasmacytoma (n = 29), extramedullary plasmacytoma (n = 10), Waldenström macroglobulinemia (WM) (n = 26), primary amyloidosis (AL) (n = 581), light chain deposition disease (LCDD) (n = 18), and POEMS syndrome (n = 31). RESULTS: Of the 1877 patients, 26 were negative in all assays. Omitting urine from the panel lost an additional 23 patients (15 MGUS, 6 AL, 1 plasmacytoma, 1 LCDD), whereas the omission of FLC lost 30 patients (6 MM, 23 AL, and 1 LCDD). The omission of serum IFE as well as urine lost an additional 58 patients (44 MGUS, 7 POEMS, 5 AL, 1 SMM, and 1 plasmacytoma). CONCLUSIONS: The major impact of using a simplified screening panel of serum PEL plus FLC rather than PEL, IFE, and FLC is an 8% reduction in sensitivity for MGUS, 23% for POEMS (7 patients), 4% for plasmacytoma (1 patient), 1% for AL, and 0.5% for SMM. There is no diminution in sensitivity for detecting MM, macroglobulinemia, and LCDD.
Authors: Mohammad R Nowrousian; Dieter Brandhorst; Christiane Sammet; Michaela Kellert; Rainer Daniels; Philipp Schuett; Miriam Poser; Siemke Mueller; Peter Ebeling; Anja Welt; Arthur R Bradwell; Ulrike Buttkereit; Bertram Opalka; Michael Flasshove; Thomas Moritz; Siegfried Seeber Journal: Clin Cancer Res Date: 2005-12-15 Impact factor: 12.531
Authors: Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton Journal: N Engl J Med Date: 2006-03-30 Impact factor: 91.245
Authors: Jerry A Katzmann; Angela Dispenzieri; Robert A Kyle; Melissa R Snyder; Matthew F Plevak; Dirk R Larson; Roshini S Abraham; John A Lust; L Joseph Melton; S Vincent Rajkumar Journal: Mayo Clin Proc Date: 2006-12 Impact factor: 7.616
Authors: Tilmann Bochtler; Ute Hegenbart; Christiane Heiss; Axel Benner; Friedrich Cremer; Martin Volkmann; Jochen Ludwig; Jolanta B Perz; Anthony D Ho; Hartmut Goldschmidt; Stefan O Schonland Journal: Haematologica Date: 2008-02-20 Impact factor: 9.941
Authors: Colin A Hutchison; Stephen Harding; Pete Hewins; Graham P Mead; John Townsend; Arthur R Bradwell; Paul Cockwell Journal: Clin J Am Soc Nephrol Date: 2008-11 Impact factor: 8.237
Authors: A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie Journal: Leukemia Date: 2008-11-20 Impact factor: 11.528
Authors: Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung Journal: J Am Soc Nephrol Date: 2011-04-21 Impact factor: 10.121
Authors: Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders Journal: Nat Rev Nephrol Date: 2011-11-01 Impact factor: 28.314
Authors: Shaji Kumar; Angela Dispenzieri; Jerry A Katzmann; Dirk R Larson; Colin L Colby; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Steve R Zeldenrust; Marina Ramirez-Alvarado; Raynell J Clark; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz Journal: Blood Date: 2010-08-26 Impact factor: 22.113
Authors: Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar Journal: Lancet Date: 2010-05-15 Impact factor: 79.321